In the US, Vorapaxar (vorapaxar systemic) is a member of the drug class protease-activated receptor-1 antagonists and is used to treat Peripheral Arterial Disease, Prevention of Atherothrombotic Events and Thromboembolic Disorder.
ATC (Anatomical Therapeutic Chemical Classification)
CAS registry number (Chemical Abstracts Service)
- Vorapaxarum (Latin)
- Vorapaxar (German)
- Vorapaxar (French)
- Vorapaxar (Spanish)
- Vorapaxar (OS: USAN)
- UNII-ZCE93644N2 (IS)
- Vorapaxar Sulfate (OS: USAN, JAN)
- UNII-IN66038E6C (IS)
- Vorapaxar Sulfate (PH: JP XVI)
Merck Sharp & Dohme Corp., United States
|JAN||Japanese Accepted Name|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
|WHO||World Health Organization|
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.